Bioplast® Fibrin Film for Conjunctival Replacement

Tapasztó, I.; Kerényi, Géza

doi:10.1111/j.1755-3768.1979.tb00522.x

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hungarian government. [68][69][70][71][72][73][74] The Hungarian IP was sold to Ethicon in the early mid 1970s, and the technology was shelved due to the advent of modern plastics as well as new concerns over the bovine-derived products. Cost was also an issue due to the high cost of isolating the large volumes of fibrinogen needed to make such plastics.…”

Section: Plasma-based Biomaterials For Tissue Repairmentioning

confidence: 99%

Biologically Active Blood Plasma-Based Biomaterials as a New Paradigm for Tissue Repair Therapies

Smith

Weiss

Burgess

et al. 2013

Disruptive Science and Technology

View full text Add to dashboard Cite

Platelets contain an array of growth factors, extracellular matrix molecules, and other signaling molecules that are released into the injury site upon platelet activation, thus providing the cues needed to help initiate and orchestrate tissue repair. In an effort to harness this activity for therapeutic use, autologous concentrated platelet-rich plasma (PRP) has become a popular therapy, particularly in sports medicine, where the desired outcome is to overcome the body's limitations to tissue repair and accelerate healing. However, the effectiveness of PRP therapies remains controversial due to variable clinical outcomes. Potential sources of variability include the different types of platelet concentrators as well as the inherent variation in patient-to-patient platelet and growth factor quality and quantity. Additionally, PRP, either activated pre-or postinjection, cannot be spatially contained in an injury site and is rapidly resorbed. A further limitation to PRP is that it is not a simple, off-the-shelf solution. We have developed solid, bioactive plasma-based biomaterials (PBMs) that may address these issues. Unlike platelet concentrators, which concentrate the platelets and subsequently discard a significant volume of plasma, we utilize the entire plasma (including the platelets), which contains vital growth factors and other components that are not platelet-derived. Pooled plasma is utilized to reduce PBM lot-to-lot variability. PBMs are inexpensive to manufacture, safe, available as off-the-shelf products, formable into complex 3D shapes, and biodegradable with tunable biomechanical and degradation properties. PBM retention of growth factor activity has been demonstrated with the use of cell proliferation assays. Biocompatibility has been established both in vitro and in vivo. Further, the initial feasibility of PBMs to stimulate the repair of a bone defect was demonstrated in a mouse calvarial defect model. Overall, PBMs represent a platform technology with significant potential to be a disruptive new therapy option in a variety of clinical applications, not only in major clinical markets, but also in third world and developing countries, where the need is high, but where the cost is a barrier to treatment.

show abstract